Literature DB >> 18575192

Consensus drug resistance mutations for epidemiological surveillance: basic principles and potential controversies.

Robert W Shafer1, Soo-Yon Rhee, Diane E Bennett.   

Abstract

Programmes that monitor local, national and regional levels of transmitted HIV-1 drug resistance inform treatment guidelines and provide feedback on the success of HIV-1 treatment and prevention programmes. The World Health Organization (WHO) has established a global programme for genotypic surveillance of HIV-1 drug resistance and has recommended the adoption of a consensus definition of genotypic drug resistance. Such a definition is necessary to accurately compare transmitted drug resistance rates across geographical regions and time periods. HIV-1 diversity and the large number of mutations associated with antiretroviral drug resistance complicate the development of a consensus definition for genotypic drug resistance. This paper reviews the data that must be considered to determine which of the many HIV-1 drug resistance mutations are likely to be both sensitive and specific indicators of transmitted drug resistance. The process used to create a previously published list of drug resistance mutations for HIV-1 surveillance is reviewed and alternative approaches to this process are discussed.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18575192      PMCID： PMC4388302     

Source DB:  PubMed          Journal:  Antivir Ther        ISSN： 1359-6535


  39 in total

1.  Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates.

Authors:  Jeannette M Whitcomb; Neil T Parkin; Colombe Chappey; Nicholas S Hellmann; Christos J Petropoulos
Journal:  J Infect Dis       Date:  2003-09-16       Impact factor: 5.226

Review 2.  Current patterns in the epidemiology of primary HIV drug resistance in North America and Europe.

Authors:  Deenan Pillay
Journal:  Antivir Ther       Date:  2004-10

Review 3.  Epidemiology of antiretroviral drug resistance in drug-naïve persons.

Authors:  Anna Maria Geretti
Journal:  Curr Opin Infect Dis       Date:  2007-02       Impact factor: 4.915

4.  Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates.

Authors:  Jeannette M Whitcomb; Wei Huang; Kay Limoli; Ellen Paxinos; Terri Wrin; Gail Skowron; Steven G Deeks; Michael Bates; Nicholas S Hellmann; Christos J Petropoulos
Journal:  AIDS       Date:  2002-10-18       Impact factor: 4.177

5.  Progressive reversion of human immunodeficiency virus type 1 resistance mutations in vivo after transmission of a multiply drug-resistant virus.

Authors:  Rajesh T Gandhi; Alysse Wurcel; Eric S Rosenberg; Mary N Johnston; Nicholas Hellmann; Michael Bates; Martin S Hirsch; Bruce D Walker
Journal:  Clin Infect Dis       Date:  2003-11-17       Impact factor: 9.079

6.  Genetic variation at NNRTI resistance-associated positions in patients infected with HIV-1 subtype C.

Authors:  Zehava Grossman; Valery Istomin; Diana Averbuch; Margalit Lorber; Klaris Risenberg; Itzchak Levi; Michael Chowers; Michael Burke; Nimrod Bar Yaacov; Jonathan M Schapiro
Journal:  AIDS       Date:  2004-04-09       Impact factor: 4.177

7.  Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir.

Authors:  Zehava Grossman; Ellen E Paxinos; Diana Averbuch; Shlomo Maayan; Neil T Parkin; Dan Engelhard; Margalit Lorber; Valery Istomin; Yael Shaked; Ella Mendelson; Daniela Ram; Chris J Petropoulos; Jonathan M Schapiro
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

8.  Quantitation of zidovudine-resistant human immunodeficiency virus type 1 in the blood of treated and untreated patients.

Authors:  H Mohri; M K Singh; W T Ching; D D Ho
Journal:  Proc Natl Acad Sci U S A       Date:  1993-01-01       Impact factor: 11.205

9.  Human immunodeficiency virus reverse transcriptase and protease sequence database.

Authors:  Soo-Yon Rhee; Matthew J Gonzales; Rami Kantor; Bradley J Betts; Jaideep Ravela; Robert W Shafer
Journal:  Nucleic Acids Res       Date:  2003-01-01       Impact factor: 16.971

10.  Assessment of automated genotyping protocols as tools for surveillance of HIV-1 genetic diversity.

Authors:  Robert Gifford; Tulio de Oliveira; Andrew Rambaut; Richard E Myers; Catherine V Gale; David Dunn; Robert Shafer; Anne-Mieke Vandamme; Paul Kellam; Deenan Pillay
Journal:  AIDS       Date:  2006-07-13       Impact factor: 4.177
View more
  26 in total

1.  Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda.

Authors:  Steven J Reynolds; Oliver Laeyendecker; Gertrude Nakigozi; Joel E Gallant; Wei Huang; Sarah E Hudelson; Thomas C Quinn; Kevin Newell; David Serwadda; Ronald H Gray; Maria J Wawer; Susan H Eshleman
Journal:  AIDS Res Hum Retroviruses       Date:  2012-04-26       Impact factor: 2.205

2.  Antiretroviral drug resistance surveillance among treatment-naive human immunodeficiency virus type 1-infected individuals in Angola: evidence for low level of transmitted drug resistance.

Authors:  Inês Bártolo; Cheila Rocha; José Bartolomeu; António Gama; Marlene Fonseca; Ana Mendes; Filipa Cristina; Sven Thamm; Marta Epalanga; Patrícia Cavaco Silva; Nuno Taveira
Journal:  Antimicrob Agents Chemother       Date:  2009-05-11       Impact factor: 5.191

3.  Viral Genetic Diversity and Polymorphisms in a Cohort of HIV-1-Infected Patients Eligible for Initiation of Antiretroviral Therapy in Abuja, Nigeria.

Authors:  Karidia Diallo; Du-Ping Zheng; Erin K Rottinghaus; Orji Bassey; Chunfu Yang
Journal:  AIDS Res Hum Retroviruses       Date:  2015-02-05       Impact factor: 2.205

4.  The HIV-1 epidemic: low- to middle-income countries.

Authors:  Yiming Shao; Carolyn Williamson
Journal:  Cold Spring Harb Perspect Med       Date:  2012-03       Impact factor: 6.915

5.  Global analysis of sequence diversity within HIV-1 subtypes across geographic regions.

Authors:  Austin Huang; Joseph W Hogan; Sorin Istrail; Allison Delong; David A Katzenstein; Rami Kantor
Journal:  Future Virol       Date:  2012-05       Impact factor: 1.831

Review 6.  The global status of HIV drug resistance: clinical and public-health approaches for detection, treatment and prevention.

Authors:  Steven Y Hong; Jean B Nachega; Karen Kelley; Silvia Bertagnolio; Vincent C Marconi; Michael R Jordan
Journal:  Infect Disord Drug Targets       Date:  2011-04

7.  Reverse transcriptase drug resistance mutations in HIV-1 subtype C infected patients on ART in Karonga District, Malawi.

Authors:  Vijay B Bansode; Simon Aa Travers; Amelia C Crampin; Bagrey Ngwira; Neil French; Judith R Glynn; Grace P McCormack
Journal:  AIDS Res Ther       Date:  2011-10-13       Impact factor: 2.250

8.  Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update.

Authors:  Diane E Bennett; Ricardo J Camacho; Dan Otelea; Daniel R Kuritzkes; Hervé Fleury; Mark Kiuchi; Walid Heneine; Rami Kantor; Michael R Jordan; Jonathan M Schapiro; Anne-Mieke Vandamme; Paul Sandstrom; Charles A B Boucher; David van de Vijver; Soo-Yon Rhee; Tommy F Liu; Deenan Pillay; Robert W Shafer
Journal:  PLoS One       Date:  2009-03-06       Impact factor: 3.240

9.  Prevalence of transmitted drug resistance and impact of transmitted resistance on treatment success in the German HIV-1 Seroconverter Cohort.

Authors:  Barbara Bartmeyer; Claudia Kuecherer; Claudia Houareau; Johanna Werning; Kathrin Keeren; Sybille Somogyi; Christian Kollan; Heiko Jessen; Stephan Dupke; Osamah Hamouda
Journal:  PLoS One       Date:  2010-10-07       Impact factor: 3.240

Review 10.  HIV-1 drug resistance and resistance testing.

Authors:  Dana S Clutter; Michael R Jordan; Silvia Bertagnolio; Robert W Shafer
Journal:  Infect Genet Evol       Date:  2016-08-29       Impact factor: 3.342
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.